

Adjuvante Therapie des Nierenzellkarzinoms: Immuntherapie als neue Option

Gunhild von Amsberg

Literatur

1. Escudier B et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2019; 30: 706–20
2. Marconi L et al. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. *Clin Genitourin Cancer* 2021; 19: e92–e9
3. Choueiri TK und Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. *N Engl J Med* 2017; 376: 354–66
4. Ravaud A et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. *New England Journal of Medicine* 2016; 375: 2246–54
5. Staehler M et al. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. *Ann Oncol* 2018; 29: 2098–104
6. Ryan CW et al. EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249). *Journal of Clinical Oncology* 2022; 40: LBA4500-LBA4500
7. Haas NB et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. *The Lancet* 2016; 387: 2008–16
8. Eisen T et al. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. *Journal of Clinical Oncology* 2020; 38: 4064–75
9. Motzer RJ et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. *Eur Urol* 2021; 79: 334–8
10. Gross-Goupil M et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. *Ann Oncol* 2018; 29: 2371–8
11. Choueiri TK et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. *New England Journal of Medicine* 2021; 385: 683–94
12. Choueiri TK et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. *Journal of Clinical Oncology* 2022; 40: 290
13. Choueiri TK et al. Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564. *Journal of Clinical Oncology* 2022; 40: 4512